Ignoring Side Effects: Failing to report new or worsening side effects to your provider
Effects of Micronutrients on Thyroid Parameters About the Author: Hari Krishnamurthy is the Director of Biomedical Engineering at Vibrant Labs
Please note - Pixels does not reimburse the outgoing or return shipping charges unless the return is due to a defect in quality
10.1038/s41467-020-14705-2
Disclosures: Cynthia Levy: Cymabay: Grant/Research Support, Cymabay: Consultant, Intercept: Grant/Research Support, Intercept: Consultant, Calliditas: Grant/Research Support, Calliditas: Consultant, GSK: Consultant, GSK: Grant/Research Support, Ipsen: Grant/Research Support, Ipsen: Consultant, Mirum: Grant/Research Support, Mirum: Consultant, Zydus: Grant/Research Support, Gilead: Grant/Research Support, Gilead: Consultant, Escient: Grant/Research Support, Kowa: Grant/Research Support, Kowa: Consultant, Genfit: Grant/Research Support, COur: Advisor, Chemomab: Consultant, Christopher Bowlus: Calliditas: Grant/Research Support, ChemoMab: Grant/Research Support, ChemoMab: Consultant, COUR Phamaceuticals: Grant/Research Support, Cymabay: Grant/Research Support, Cymabay: Consultant, Cymabay: Consultant, Gilead: Grant/Research Support, GSK Pharmaceuticals: Grant/Research Support, GSK Pharmaceuticals: Consultant, Hanmi: Grant/Research Support, Intercept: Grant/Research Support, Invea Therapeutics: Consultant, Ipsen: Grant/Research Support, Ipsen: Consultant, Mirum: Grant/Research Support, NGM Bio: Consultant, Novartis: Grant/Research Support, Novo Nordisk: Grant/Research Support, Pliant Therapeutics: Grant/Research Support, Pliant Therapeutics: Consultant, Viking Therapeutics: Grant/Research Support, Zydus Therapeutics: Grant/Research Support, Eric Lawitz: Nothing to Disclose, Nuno Antunes: Nothing to Disclose, Benjamin Miller: Ipsen: Employee, Ipsen: Stock - publicly traded company, Jianfen Shu: Nothing to Disclose, Claudia Zein: Ipsen: Employee, Kris Kowdley: Nothing to Disclose 2346 TREATMENT RESPONSE IN PRIMARY BILIARY CHOLANGITIS BASED ON DIFFERING CRITERIA Ana Maria Davila Morales 1 Kesany Boupapanh 1 Zoe Post 1 Nancy Reau 1 , 1 Rush University Medical Center Background: Primary biliary cholangitis (PBC) is a chronic autoimmune cholestatic liver disease commonly associated with women aged 40 or older, high levels of alkaline phosphatase (ALP), and antimitochondrial autoantibodies (AMA)
